Avenzo's People Play: Inside the Strategic Hire Fueling a Biotech IPO

SAN DIEGO, CA – August 24, 2026 – In a move that signals a significant operational ramp-up, clinical-stage oncology firm Avenzo Therapeutics announced today the appointment of Connie Wedel as its new Chief Human Resources Officer. While executive appointments are routine, this one warrants a closer look, revealing a carefully orchestrated strategy as Avenzo prepares to transition into a publicly traded entity with an ambitious, multi-asset pipeline.

Wedel, who brings over two decades of life sciences HR leadership, joins the executive team at what CEO Dr. Athena Countouriotis calls a “pivotal stage.” The company is expanding, preparing to operate publicly, and advancing four clinical-stage programs. “Connie’s experience in building HR teams and high-performance cultures will be instrumental as we continue to scale and position the company for long-term success,” Countouriotis stated.

This appointment is a classic example of operational innovation—placing the right leadership in place not just for the company that exists today, but for the one it intends to become tomorrow. For Avenzo, that future involves navigating the intense scrutiny of public markets and winning a fierce war for specialized talent.

Fortifying for the Public Stage

Avenzo is not merely “preparing” for public life; it is actively engineering its debut. In June, the company announced a definitive merger agreement with the publicly listed Rallybio Corporation. The deal, expected to close in the fourth quarter of 2026, will see the combined entity operate as Avenzo Therapeutics and trade on the Nasdaq under the ticker “AVZO.”

This reverse merger is backed by an oversubscribed $215 million private placement (PIPE) from a roster of top-tier healthcare investors. This infusion, on top of the nearly $450 million raised since its 2022 founding, provides a projected cash runway into late 2028. Such financial fortification is a powerful signal of stability in a biotech sector still regaining its footing after a period of volatility.

Entering the public markets necessitates a complete overhaul of a company’s internal machinery. This is where Wedel’s role becomes mission-critical. A private, venture-backed startup operates with a different set of rules and pressures than a public company accountable to shareholders and SEC regulations. Building the HR infrastructure to manage public company compensation plans, robust compliance protocols, and the rapid scaling of personnel is a monumental task. Wedel’s background, which includes leadership roles at firms like The Binding Site through its acquisition by Thermo Fisher Scientific, suggests she is well-versed in navigating such high-stakes transitions.

An Engine Room Demanding Talent

The strategic imperative for this hire becomes even clearer when examining Avenzo’s clinical engine room. The company is not a single-asset pony; it is advancing a diversified portfolio of four distinct oncology programs, each requiring specialized teams to shepherd them through complex clinical and regulatory pathways.

Its lead small molecule, AVZO-021, a CDK2 inhibitor, showed encouraging Phase 1 results at the ASCO meeting in June, demonstrating a favorable tolerability profile in heavily pretreated breast cancer patients. This asset is now being studied in combination with its sister compound, the CDK4 inhibitor AVZO-023, in a triplet-therapy trial aimed at overcoming treatment resistance—a major challenge in oncology.

Beyond small molecules, Avenzo is pushing forward with two sophisticated antibody-drug conjugates (ADCs). AVZO-1418 is a bispecific ADC targeting EGFR/HER3, in-licensed from DualityBio, while AVZO-103 is a bispecific ADC targeting Nectin4/TROP2. The latter has already received FDA Fast Track designation for advanced urothelial cancer, underscoring its potential clinical urgency. Advancing four programs in parallel, from Phase 1/2 studies towards potential pivotal trials, creates an exponential demand for talent in clinical operations, regulatory affairs, data science, and process development.

The People Architect in a Cautious Market

Avenzo’s aggressive clinical strategy is unfolding against the backdrop of a transformed biotech labor market. The “Great Resignation” has given way to a “Great Rebound,” where professionals, rattled by recent industry-wide layoffs, are more cautious. They are scrutinizing a company’s financial stability, pipeline viability, and culture before making a move.

This is precisely the environment where a leader like Wedel can create a competitive advantage. Described as a “people architect,” her career has focused on building the very high-performance, inclusive cultures that attract and retain top-tier talent. Her experience at Cytek Biosciences and Argen Corporation, coupled with her academic work teaching organizational behavior at UC San Diego, provides a foundation in both the practice and theory of building elite teams.

“I’m excited to join Avenzo at such an exciting stage of its growth,” Wedel stated. Her focus on investing in people and culture will be key to translating Avenzo’s financial war chest and promising science into a thriving, productive organization.

By bringing in a seasoned HR strategist before the public listing is even finalized, Avenzo is making a forward-looking investment in its human capital infrastructure. The move demonstrates a sophisticated understanding that in the high-stakes world of oncology drug development, the most valuable assets are not just the molecules in the pipeline, but the people who guide them from the lab to the patient.